AI-minded builder of online health networks raises $9.44M

MyHealthTeams, a San Francisco-based creator of social networks for patients with chronic health conditions, has raised a fresh $9.44 million to expand its existing online spaces and launch new ones.

In announcing the funding, led by Belgium-based UCB, MyHealthTeams noted its “smart recommendations” for patients use natural language processing and machine learning to tailor education and guidance.

The company says its reach already extends to 2 million registered members across 33 condition-specific patient social networks.

It recently expanded into 13 English-speaking countries and is partnering with “nine of the top 10 global pharmaceutical companies and 19 other biopharma and healthcare companies that share MyHealthTeams’ focus on addressing unmet patient needs,” according to the announcement.

UCB unit leader Taco van Tiel said his firm’s investment “reflects our ambition to transform the lives of people living with severe diseases,” adding that UCB is concentrating on addressing “the unmet needs of these patients [to] bring them differentiated solutions that make a meaningful difference in their lives.”

MyHealthTeams says the new funding brings its total take from investors to $26.84 million.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.